Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject).~* The subject must have completed the end of treatment visit of NN1250-3643 with Insulin degludec once daily + metformin.~* Ability and willingness to adhere to the protocol including self measurement of plasma glucose according to the protocol~Exclusion Criteria:~* Participated in NN1250-3643 and treated with insulin glargine~* Previous treatment with glucacon like peptide (GLP-1) receptor agonists (e.g. exenatide, liraglutide)~* Impaired liver function, defined as alanine aminotransferase (ALAT) 2.5 times the upper limit of normal at end of treatment in NN1250-3643~* Impaired renal function defined as serum-creatinine = 125 µmol/l (= 1.4 mg/dl) for males and = 110 µmol/L (= 1.3 mg/dl) for females or according to local label for metformin \[For France: glomerular filtration rate below 60 ml/min, calculated by the Cockroft \& Gault formula\] at end of treatment in NN1250-3643.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDeg (non-randomised) (Type: EXPERIMENTAL): None
- IDeg + IAsp (Type: EXPERIMENTAL): None
- IDeg + liraglutide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).